LONDON, June 20,
2024 /PRNewswire/ -- New state of the art
testing for identifying the risk of hereditary cancer is to be
launched in the UK.
Comprehensive hereditary germline cancer testing is
designed to accurately predict if family members of cancer patients
are at increased risk from the disease.
A pan-cancer test which achieves 99% sensitivity and identifies
mutations in 70 genes known to be associated with cancers which
have a strong inherited, genetic component, including prostate,
breast, colorectal, pancreatic and ovarian cancers, will be made
available to health professionals later this summer.
EDX Medical plc, based in Cambridge, which develops innovative digital
diagnostic products and services supporting personalised treatments
for patients with major diseases will introduce the tests and
support services.
Comprehensive hereditary germline cancer testing will enable
doctors to advise family members of cancer patients on lifestyle
choices and actions they can take to delay or prevent onset of the
disease.
The tests will be available through private healthcare providers
and via specific NHS Genetic and Genomic Testing Centres in cases
where family members of cancer patients can be screened for genetic
risk of cancer. EDX Medical will provide a support
service for healthcare professionals with the test.
Professor Sir Chris Evans, OBE,
founder of EDX Medical plc, commented: " We are delighted to
announce the launch of this test which we believe to be the highest
quality hereditary cancer test available anywhere in the
world. The fact that this single test covers all the
known genes associated with inherited cancer risk will be
enormously reassuring for people who have a close family member
with or who have survived cancer.
"This is an important development in the EDX Medical cancer
strategy to ensure increasing accessibility to excellent diagnostic
products for doctors and their patients in the UK. The hereditary
test is the first in a series of new precision cancer tests to be
launched by EDX Medical in the coming months".
Dr Mike Hudson, CEO, EDX Medical
plc, said:" This is an excellent, comprehensive test based on the
latest clinical and scientific knowledge. Testing family
members of cancer patients must be a key part of a National Cancer
Prevention and Management Strategy".
"This test enables doctors to identify important genetic risks
shared by patients and their families, to take preventative action
before the onset of disease, or to make well-informed clinical
decisions and ensure access to modern medicines with greater
chances of long-term survival should cancer occur later".
About EDX Medical Group
www.edxmedical.com
EDX Medical Group Plc develops innovative digital
diagnostic products and services, enabling cost effective and
timely delivery of personalised treatment for cancer, heart disease
and infectious diseases. The company is listed on the Access
Segment of the AQSE Growth Market (TIDM: EDX).
View original
content:https://www.prnewswire.co.uk/news-releases/new-tests-to-identify-hereditary-cancer-risks-to-be-launched-302177212.html